Literature DB >> 2363050

Functional domains and upstream activation properties of cloned human TATA binding protein.

M G Peterson1, N Tanese, B F Pugh, R Tjian.   

Abstract

The TATA binding protein, TFIID, plays a central role in the initiation of eukaryotic mRNA synthesis. Here, we present a human cDNA clone for this factor. Comparison of its predicted protein sequence with those from Drosophila and yeast reveals a highly conserved carboxyl-terminal 180 amino acids. By contrast, the amino-terminal region of TFIID has diverged in both sequence and length. A striking feature of the human protein is a stretch of 38 glutamine residues in the NH2-terminal region. Expression of human TFIID in both Escherichia coli and HeLa cells produces a protein that binds specifically to a TATA box and promotes basal transcription; the conserved COOH-terminal portion of the protein is sufficient for both of these activities. Recombinant TFIID forms a stable complex on a TATA box either alone or in combination with either of the general transcription factors, TFIIA or TFIIB. Full-length recombinant TFIID is able to support Sp1 activated transcription in a TFIID-depleted nuclear extract, while a deletion of the NH2-terminal half of the protein is not. These results indicate the importance of the NH2-terminal region for upstream activation functions and suggest that additional factors (co-activators) are required for mediating interactions with specific regulators.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2363050     DOI: 10.1126/science.2363050

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  166 in total

1.  Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.

Authors:  J M Lecerf; T L Shirley; Q Zhu; A Kazantsev; P Amersdorfer; D E Housman; A Messer; J S Huston
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

2.  Requirement for TAF(II)250 acetyltransferase activity in cell cycle progression.

Authors:  E L Dunphy; T Johnson; S S Auerbach; E H Wang
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

Review 3.  Cytopathogenesis and inhibition of host gene expression by RNA viruses.

Authors:  D S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2000-12       Impact factor: 11.056

4.  Functional binding of the "TATA" box binding component of transcription factor TFIID to the -30 region of TATA-less promoters.

Authors:  S R Wiley; R J Kraus; J E Mertz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

5.  Cloning and chromosomal mapping of a human immunodeficiency virus 1 "TATA" element modulatory factor.

Authors:  J A Garcia; S H Ou; F Wu; A J Lusis; R S Sparkes; R B Gaynor
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

6.  In vivo transcriptional analysis of the TATA-less promoter of the Drosophila melanogaster vermilion gene.

Authors:  Y W Fridell; L L Searles
Journal:  Mol Cell Biol       Date:  1992-10       Impact factor: 4.272

7.  TFIIA induces conformational changes in TFIID via interactions with the basic repeat.

Authors:  D K Lee; J DeJong; S Hashimoto; M Horikoshi; R G Roeder
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

8.  Relationship among location of T-antigen-induced DNA distortion, auxiliary sequences, and DNA replication efficiency.

Authors:  Susan Okuley; Mindy Call; Tara Mitchell; Bugen Hu; Mary E Woodworth
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Requirements for activation of the herpes simplex virus glycoprotein C promoter in vitro by the viral regulatory protein ICP4.

Authors:  B Gu; N DeLuca
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  The bZIP domains of Fos and Jun mediate a physical association with the TATA box-binding protein.

Authors:  L J Ransone; L D Kerr; M J Schmitt; P Wamsley; I M Verma
Journal:  Gene Expr       Date:  1993
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.